↓ Skip to main content

Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer

Overview of attention for article published in PharmacoEconomics, September 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

policy
1 policy source
twitter
8 X users

Citations

dimensions_citation
146 Dimensions

Readers on

mendeley
124 Mendeley
Title
Years of Potential Life Lost and Indirect Costs of Melanoma and Non-Melanoma Skin Cancer
Published in
PharmacoEconomics, September 2012
DOI 10.2165/11589300-000000000-00000
Pubmed ID
Authors

Gery P. Guy, Donatus U. Ekwueme

Abstract

Skin cancer is the most common form of cancer in the US, and an important public health concern both in the US and throughout the world. Given high incidence rates among young adults and the large number of deaths, skin cancer has the potential to result in significant years of potential life lost (YPLL) and lost productivity. The purpose of this study was to systematically review the published literature on the YPLL and the value of productivity loss from morbidity and premature mortality resulting from melanoma and non-melanoma skin cancer (NMSC). Employing pre-defined search terms and inclusion/exclusion criteria, systematic searches were conducted in MEDLINE, EMBASE, CINAHL and Econlit. We selected studies that measured the societal burden of melanoma and NMSC - through estimating either the YPLL and/or the indirect costs. We identified 16 relevant studies meeting our criteria, six were from the US and ten were from other industrialized countries; ten of the studies reported results on YPLL, eight on mortality costs and five on morbidity costs. Some studies reported results in more than one category. From each eligible article and report, we extracted detailed information on the study population/country, study design, data analysis methods and study results. Data abstracted for each eligible study included estimated number of YPLL, YPLL per death and morbidity and mortality costs. The average number of YPLL per death was approximately 15 for melanoma and 10 for NMSC. We found the costs attributable to melanoma and NMSC ranged from $US39.2 million to $US28.9 million for morbidity and $US3.3 billion to $US1.0 billion for mortality, respectively. It is clear from the published literature that skin cancer leads to significant YPLL and indirect costs associated with premature mortality and morbidity. Prevention and early detection efforts are important in helping reduce the incidence of melanoma and NMSC, and the related deaths and productivity losses.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Denmark 1 <1%
Germany 1 <1%
Canada 1 <1%
Brazil 1 <1%
Unknown 120 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 26 21%
Student > Ph. D. Student 23 19%
Student > Master 22 18%
Other 10 8%
Student > Bachelor 8 6%
Other 15 12%
Unknown 20 16%
Readers by discipline Count As %
Medicine and Dentistry 44 35%
Biochemistry, Genetics and Molecular Biology 9 7%
Agricultural and Biological Sciences 6 5%
Pharmacology, Toxicology and Pharmaceutical Science 5 4%
Engineering 4 3%
Other 28 23%
Unknown 28 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2014.
All research outputs
#3,621,892
of 25,373,627 outputs
Outputs from PharmacoEconomics
#359
of 1,992 outputs
Outputs of similar age
#25,820
of 189,942 outputs
Outputs of similar age from PharmacoEconomics
#63
of 550 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,992 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,942 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 550 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.